Orilissa, also known by its generic name elagolix, is a medication approved for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women and endometriosis pain [1][2]. Clinical studies have been instrumental in establishing its efficacy and safety.
What are the key findings from Orilissa's clinical trials?
The clinical development of Orilissa involved several pivotal trials. For endometriosis, two Phase 3 trials, known as ELARIS ENDO-1 and ELARIS ENDO-2, demonstrated that Orilissa significantly reduced menstrual pain and non-menstrual pelvic pain associated with endometriosis [3]. These studies also showed a reduction in the occurrence of endometriotic lesions [3]. For heavy menstrual bleeding due to uterine fibroids, two Phase 3 trials, LYRA-1 and LYRA-2, found that Orilissa effectively reduced menstrual blood loss and improved the quality of life for patients [4]. In these trials, a significant proportion of women achieved a reduction in menstrual blood loss to less than 80 mL [4].
How does Orilissa work to treat endometriosis and fibroids?
Orilissa functions as a gonadotropin-releasing hormone (GnRH) antagonist [1]. It works by blocking the action of GnRH in the brain, which in turn reduces the production of estrogen and progesterone by the ovaries [1][5]. Both estrogen and progesterone can stimulate the growth of uterine fibroids and the tissue that causes endometriosis [5]. By lowering these hormone levels, Orilissa helps to shrink fibroids and alleviate the symptoms of endometriosis [1][5].
What were the main side effects observed in Orilissa studies?
The most common side effects reported in clinical trials for Orilissa included headache, nausea, and abdominal pain [1][3][4]. However, a significant concern noted in studies was the potential for bone mineral density loss due to the reduction in estrogen levels [1][6]. For this reason, Orilissa is typically prescribed at the lowest effective dose for the shortest duration necessary [1]. Monitoring of bone density may be recommended, particularly for patients with risk factors for osteoporosis [6].
Are there different dosage strengths or treatment durations for Orilissa?
Orilissa is available in two dosage strengths: 150 mg once daily and 200 mg twice daily [1]. The 150 mg dose is generally recommended for treatment of endometriosis-associated pain for up to 24 months [3]. The 200 mg dose, taken twice daily, is indicated for the management of heavy menstrual bleeding associated with uterine fibroids for up to 24 months [4]. Extended treatment durations beyond 24 months are typically reserved for those on the 150 mg dose, and the decision to continue treatment should involve a careful assessment of risks and benefits [1].
When does Orilissa's patent expire?
Information on the specific patent expiration dates for Orilissa can be found through specialized drug patent databases. For instance, DrugPatentWatch.com provides detailed information on patents, exclusivity periods, and potential generic entry dates for various medications, including Orilissa [7]. These dates are crucial for understanding when generic versions of the drug may become available.